Telomerase gene mutation screening and telomere overhang detection in Chinese patients with acute myeloid leukemia

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1437-1441

  Yan, Siyi ^a   Han, Bing ^a   Wu, Yongji ^a   Zhou, Daobin ^a   Zhao, Yongqiang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; Prognosis; Telomerase gene mutation; Telomere overhang

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE RNA COMPONENT; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SHORT TERM SURVIVAL; TELOMERE HOMEOSTASIS; TELOMERE OVERHANG LENGTH;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; TELOMERASE; TELOMERE; TELOMERE SHORTENING; YOUNG ADULT;

EID: 84879379798     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.729834     Document Type: Article

References (22)

1. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-527.
2. Ram R, Uziel O, Lahav M. The importance of the telomere and telomerase system in hematological malignancies. Leuk Lymphoma 2005;46:1121-1135. (Pubitemid 41087016)
3. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for tlomere shortening. Cell 1997; 88: 657-666. (Pubitemid 27152408)
4. Calado RT, Regal JA, Kajigaya S, et al. Erosion of telomeric single-stranded overhang in patients with aplastic anaemia carrying telomerase complex mutations. Eur J Clin Invest 2009;39 : 1025-1032.
5. Mattarocci S, D ' Ambrosio E, Tafaro L, et al. Erosion of telomeric 3 ' overhangs in white blood cells of aged subjects with high frequency of very short telomeres. Mech Ageing Dev 2011; 132: 27-32.
6. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401-413. (Pubitemid 28093017)
7. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-514. (Pubitemid 29231173)
8. Br ü mmendorf TH, Rufer N, Holyoake TL, et al. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. Ann NY Acad Sci 2001;938:293-303 ; discussion 303-304.
9. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998; 19: 32-38. (Pubitemid 28242019)
10. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555.
11. Kirwan M, Vulliamy T, Marrone A, et al. Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Hum Mutat 2009;30:1567-1573.
12. Han B, Liu B, Cui W, et al. Telomerase gene mutation screening in Chinese patients with aplastic anemia. Leuk Res 2010;34 : 258-260.
13. National Comprehensive Caner Network. Acute Myeloid Leukemia NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ), Version 2. 2011. p 21 [Internet]. Available from:http://www.nccn.org/professionals/physician-gls/f- guidelines.asp
14. Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci USA 2009;106:1187-1192.
15. Capraro V, Zane L, Poncet D, et al. Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Exp Hematol 2011;39:195-202.
16. Borssén M, Cullman I, Norén-Nyström U, et al. HTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup. Exp Hematol 2011; 39: 1144-1151.
17. Cimino-Reale G, Pascale E, Battiloro E, et al. The length of telomeric G-rich strand 3 '-overhang measured by oligonucleotide ligation assay. Nucleic Acids Res 2001; 29: E35.
18. Hartmann U, Br ü mmendorf TH, Balabanov S, et al. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005;90:307-316. (Pubitemid 40388980)
19. Lange K, Hilm L, Nielsen KV, et al. Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010;49:260-269.
20. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
21. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-4336. (Pubitemid 35429670)
22. Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA 2010;304:1358-1364.